Splenic infarction: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 39: | Line 39: | ||
== Treatment == | == Treatment == | ||
[[Splenic infarction medical therapy|Medical Therapy]] | [[Splenic infarction surgery|Surgery]] | [[Splenic infarction primary prevention|Primary Prevention]] | [[Splenic infarction secondary prevention|Secondary Prevention | [[Splenic infarction medical therapy|Medical Therapy]] | [[Splenic infarction surgery|Surgery]] | [[Splenic infarction primary prevention|Primary Prevention]] | [[Splenic infarction secondary prevention|Secondary Prevention]] | [[Splenic infarction cost-effectiveness of therapy | Cost Effectiveness of Therapy]] | [[Splenic infarction future or investigational therapies|Future or Investigational Therapies]] | ||
==Case Studies== | ==Case Studies== | ||
Revision as of 16:18, 21 September 2012
| Splenic infarction | |
 | |
|---|---|
| Two large splenic infarcts, as demonstrated on an abdominal CT scan (white arrows) in a 36-year-old Caucasian woman with acute cytomegalovirus infection. The patient was also found to be heterozygous for the Factor V Leiden mutation. | |
| ICD-10 | D73.5 |
| DiseasesDB | 12365 |
| MedlinePlus | 001293 |
| MeSH | D013159 |
|
Splenic infarction Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Splenic infarction On the Web |
|
American Roentgen Ray Society Images of Splenic infarction |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Synonyms and keywords: Spleen infarct
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Splenic Infarction from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Ultrasound | Other Imaging Studies | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost Effectiveness of Therapy | Future or Investigational Therapies